文献速递临床试验与 GCP医学人工智能与信息学

每日生活接纳承诺疗法在早期精神病中的疗效:多中心随机对照试验研究方案

Efficacy of Acceptance and Commitment Therapy in Daily Life (ACT-DL) in early psychosis: study protocol for a multi-centre randomized controlled trial.
PubMed 文献 · Trials · 2019-12-26

INTERACT研究是一项多中心随机对照试验,旨在评估每日生活接纳承诺疗法(ACT-DL)对超高风险状态(UHR)或首发精神病(FEP)个体的疗效。研究将16-65岁患者随机分配至ACT-DL联合常规治疗(TAU)组或仅TAU组,主要结局为精神病体验相关痛苦,并在基线、干预后及6、12个月随访评估。

要点

  • ACT-DL是新型生态瞬时干预,针对UHR和FEP个体的精神病体验及社会功能。
  • 试验采用盲法评估,主要结局为精神病体验相关痛苦,随访至干预后12个月。
  • 若有效,ACT-DL有望推进早期精神病治疗并支持mHealth在精神卫生服务中的应用。

核心结论

  • 该研究是首个在UHR和FEP个体中测试ACT-DL疗效的试验,若成功可能显著推进治疗并支持mHealth干预实施。

研究设计与样本

  • 多中心随机对照试验,纳入16-65岁UHR或FEP个体,随机分配至ACT-DL联合TAU组或仅TAU组,TAU包括常规精神卫生保健及适用时的CBTp。
  • 结局在基线、干预后(8周干预结束后)、6个月和12个月随访时由盲法评估者评定。

关键数值与推荐

  • 主要结局为与精神病体验相关的痛苦;次要结局包括(瞬时)精神病体验、社会功能和精神病理性。
  • 过程测量包括心理灵活性、压力敏感性和奖赏体验,并评估ACT-DL的可接受性、治疗依从性和治疗保真度。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: Psychotic experiences, social functioning and general psychopathology are important targets for early intervention in individuals with Ultra-High-Risk state (UHR) and a first-episode psychosis (FEP). Acceptance and Commitment Therapy (ACT) is a promising, next-generation Cognitive Behavioural Therapy (CBT) that aims to modify these targets, but evidence on sustainable change and its underlying mechanisms in individuals' daily lives remains limited. The aim of the INTERACT study is to investigate the efficacy of a novel ecological momentary intervention, Acceptance and Commitment Therapy in Daily Life (ACT-DL) in a multi-centre randomised controlled trial of individuals with UHR or FEP. METHODS/DESIGN: In a multi-centre randomised controlled trial, individuals aged 16-65 years with UHR or FEP will be randomly allocated to ACT-DL in addition to treatment as usual (TAU) as the experimental condition or a control condition of TAU only, which will include - for the entire study period - access to routine mental health care and, where applicable, CBT for psychosis (CBTp). Outcomes will be assessed at baseline (i.e. before randomisation), post-intervention (i.e. after the 8-week intervention period), and 6-month and 12-month follow-ups (i.e. 6 and 12 months after completing the intervention period) by blinded assessors. The primary outcome will be distress associated with psychotic experiences, while secondary outcomes will include (momentary) psychotic experiences, social functioning and psychopathology. Process measures to assess putative mechanisms of change will include psychological flexibility, stress sensitivity and reward experiences. In addition, acceptability, treatment adherence and treatment fidelity of ACT-DL will be assessed. DISCUSSION: The current study is the first to test the efficacy of ACT-DL in individuals with UHR and FEP. If this trial demonstrates the efficacy of ACT-DL, it has the potential to significantly advance the treatment of people with UHR and FEP and, more generally, provides initial support for implementing mHealth interventions in mental health services. TRIAL REGISTRATION: Netherlands Trial Register, ID: NTR4252. Registered on 26 September 2013.

来源:Trials,查看原文。版权归原作者所有。

引用

  1. Reininghaus U, Klippel A, Steinhart H, et al. Efficacy of Acceptance and Commitment Therapy in Daily Life (ACT-DL) in early psychosis: study protocol for a multi-centre randomized controlled trial. Trials. 2019. PMID: 31878966. doi:10.1186/s13063-019-3912-4

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。